El Paso backs grant application to help fund I-10 deck plaza project
The multimillion-dollar plan is a major infrastructure project that would create a public space above the downtown stretch of the freeway.
The application is for the Transportation Alternatives Program (TAP), a federally funded, state-administered grant.
If approved, it would help pay for some features of the deck plaza, such as trails, sidewalks, and green spaces.
'This is just one little puzzle piece,' District 8 Councilmember Chris Canales said. 'But I've said from the beginning, I'd support this project as long as the money comes from state, federal, or philanthropic sources.'
The application is due this month, and a decision is expected in October. If awarded, the Texas Department of Transportation (TxDOT) would take the lead on construction, and the City of El Paso would assist with project management.
'If we are awarded, there are a lot of other steps that need to happen for the council to enter into an agreement to use that funding source, and that's something that would happen in the future,' Joaquin Rodriguez, director of grant-funded programs for the city, said.
This isn't the only funding the city is pursuing for the deck plaza. In May, the council also submitted a separate request for $4 million through the Community Project Funding program, which goes through U.S. Rep. Veronica Escobar, D-Texas, office. That funding would help cover structural elements like retaining walls and utility infrastructure.
City officials add that both funding requests are part of a larger effort to move the multimillion-dollar project forward with the goal of using outside money to make it happen.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 hours ago
- Business Wire
BiVACOR Total Artificial Heart Accepted into FDA's Total Product Life Cycle (TAP) Program
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), today announced that its TAH System has been accepted into the U.S. Food and Drug Administration's (FDA) prestigious Total Product Life Cycle (TPLC) Advisory Program, also known as the TAP program. This milestone further solidifies BiVACOR's collaboration with the FDA following the TAH's earlier recognition this year as a Breakthrough Device. This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology. The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with urgency and magnitude of our mission. Share The TAP program is a transformative FDA initiative designed to accelerate the development and patient access to high-impact medical technologies. Entry into the program provides BiVACOR with proactive, strategic engagement with the FDA throughout the entire product life cycle, from development to commercialization, supporting more efficient, risk-informed decision-making. TAP participation is reserved for breakthrough-designated devices with the potential to significantly improve patient outcomes for serious or life-threatening conditions. 'Acceptance into the TAP program marks a major milestone not just for BiVACOR, but for the field of mechanical circulatory support as a whole,' said Daniel Timms, Founder and Chief Technology Officer of BiVACOR. 'The BiVACOR TAH has the potential to fundamentally redefine the standard of care for patients with end-stage heart failure. TAP access gives us a powerful framework for working hand-in-hand with the FDA to bring this technology to the patients who need it most.' The BiVACOR TAH is intended for use as a bridge to transplant in adults with severe, irreversible biventricular or univentricular heart failure, particularly for patients who cannot be treated with traditional left ventricular assist devices (LVADs). The system employs a magnetically levitated centrifugal pump, inspired by space and industrial technologies, which provides continuous, pulsatile, and physiologically responsive cardiac support. The FDA's acceptance letter to BiVACOR emphasized that the TAP program's inclusion reflects the agency's confidence in the technology's potential to transform clinical practice. As part of the program, BiVACOR will receive more regulatory guidance, earlier identification of scientific and evidentiary gaps, and greater coordination among stakeholders, including payers and patient advocacy groups. 'This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology,' said William Cohn, MD, BiVACOR Chief Medical Officer and renowned cardiac surgeon. 'The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with the urgency and magnitude of our mission to bring a durable, fully implantable artificial heart to patients with no other options.' The TAP program was established as part of the FDA's efforts to modernize device development oversight and ensure the U.S. remains at the forefront of medical innovation. The program currently operates as a pilot under the Center for Devices and Radiological Health (CDRH), with acceptance based on strict criteria outlined in the Federal Register (87 FR 61605). BiVACOR's participation in TAP follows several recent milestones for the company, including its first-in-human implant as a bridge to support a patient awaiting a cardiac transplant. The company is now progressing toward expanded clinical trials in the U.S. and internationally. For more information on the FDA's TAP program, visit: Participation in the FDA's Total Product Life Cycle Advisory Program (TAP) does not imply FDA approval, clearance, or authorization. Inclusion in the TAP Pilot does not guarantee future marketing authorization or a regulatory outcome. The BiVACOR TAH is currently used as an investigational device and is not approved for commercial use. About BiVACOR BiVACOR ® is a clinical-stage medical device company developing a fully implantable, magnetically levitated Total Artificial Heart for long-term support of patients with end-stage biventricular heart failure. Founded by biomedical engineer Daniel Timms, PhD, and backed by leading experts in cardiovascular medicine including Dr. William E. Cohn and Dr. O.H. (Bud) Frazier, the company is conducting an FDA-approved Early Feasibility Study in the U.S. Headquartered in Huntington Beach, CA, with clinical operations in Houston and engineering offices in Gold Coast, Australia, BiVACOR is committed to addressing the global shortage of donor hearts through advanced, scalable technology. Learn more at
Business Insider
a day ago
- Business Insider
Aluminum Tariffs Weigh on Canadian Beer Maker Molson Coors (TAP)
The stock of Molson Coors (TAP) is down after the Canadian beer maker warned that aluminum tariffs are likely to hurt its profits this year. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company, which is co-headquartered in Montreal and Chicago, forecast a bigger drop in its annual profit due to tariff impacts on the cost of its aluminum beer cans. Management also cited macroeconomic uncertainty in the U.S. as a reason for its gloomy outlook. The company, which produces most of its beer at U.S.-based breweries in Colorado, nevertheless faces a 50% tariff on aluminum metal that's shipped into the U.S. In June of this year, U.S. President Donald Trump doubled the aluminum tariff from 25% previously. Alcohol Spending Molson Coors says that President Trump's fluctuating tariff policies have pressured consumer spending and led people to pare back their discretionary spending on items such as alcohol. As a result, the company expects its annual earnings to decline 7% to 10% compared to its prior forecast of a low single-digit increase. For this year's second quarter, Molson Coors reported that its net sales fell 1.6% to $3.2 billion, but came in ahead of analyst estimates of $3.1 billion. The company posted Q2 earnings per share (EPS) of $2.05, beating consensus estimates of $1.83. TAP stock has fallen 13% this year. Is TAP Stock a Buy? The stock of Molson Coors has a consensus Moderate Buy rating among 16 Wall Street analysts. That rating is based on six Buy and 10 Hold recommendations issued in the last three months. The average TAP price target of $59.73 implies 23.90% upside from current levels. These ratings are likely to change after the company's financial results.
Yahoo
2 days ago
- Yahoo
Molson Coors Brewing (TAP) Q2 Earnings and Revenues Top Estimates
Molson Coors Brewing (TAP) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $1.92 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +12.02%. A quarter ago, it was expected that this beer maker would post earnings of $0.8 per share when it actually produced earnings of $0.5, delivering a surprise of -37.5%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Molson Coors, which belongs to the Zacks Beverages - Alcohol industry, posted revenues of $3.2 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.61%. This compares to year-ago revenues of $3.25 billion. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Molson Coors shares have lost about 15.2% since the beginning of the year versus the S&P 500's gain of 7.6%. What's Next for Molson Coors? While Molson Coors has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Molson Coors was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.08 on $3.12 billion in revenues for the coming quarter and $5.87 on $11.36 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Beverages - Alcohol is currently in the bottom 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Brown-Forman B (BF.B), is yet to report results for the quarter ended July 2025. The results are expected to be released on August 28. This company is expected to post quarterly earnings of $0.37 per share in its upcoming report, which represents a year-over-year change of -9.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Brown-Forman B's revenues are expected to be $918.14 million, down 3.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Molson Coors Beverage Company (TAP) : Free Stock Analysis Report Brown-Forman Corporation (BF.B) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
